PMC5769300_01
PMC5769300_02
Second patient. Evaluation of the response to positron emission tomography (A) before and (B) after 3 cisplatin etoposide cycles.
ol-15-01-0048-g01.jpg
PMC5769300_02_ol-15-01-0048-g01.jpg
f2-ol-0-0-7263
PET revealed an intense hypermetabolism of the liver metastasis and primary lesion (Fig. 2). The first evaluation after 3 cycles by PET showed a metabolic complete response on the primary oesogastric lesion and metabolic partial response on the metastatic liver lesions (Fig. 2).
Second Patient. Evaluation of alpha-fetoprotein level, before and after chemotherapy. AFP, alpha-fetoprotein; EP, etoposide + cisplatin; CE, carboplatin + etoposide; XELIRI, irinotecan + capecitabin.
ol-15-01-0048-g02.jpg
PMC5769300_02_ol-15-01-0048-g02.jpg
f3-ol-0-0-7263
A systemic chemotherapy was delivered associating cisplatin 25 mg/m2 with etoposide 100 mg/m2 each day, day 1 to day 3, every 3 weeks, with a rapid decrease of pain, after the first cycle, although an initial increase of tumoral markers was observed (Fig. 3). A second line treatment with carboplatin and etoposid was carried out leading to a novel decrease of AFP levels before observing any progression (Fig. 3).